Literature DB >> 15877082

Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes.

Frank Grünebach1, Katrin Kayser, Markus M Weck, Martin R Müller, Silke Appel, Peter Brossart.   

Abstract

Ribonucleic acid (RNA) transfection of dendritic cells (DCs) was shown to be highly efficient in eliciting CD8+ and CD4+ T-cell responses. We analyzed whether electroporation of DCs with RNA coding for a tumor-associated antigen (TAA) would elicit antigen-specific effector cytotoxic T lymphocyte (CTL) responses and whether these responses could be modulated by cotransfection with a second specific synthetic RNA. Therefore in vitro generated human monocyte-derived DCs were electroporated with in vitro transcribed RNA (in vitro transcript, IVT) encoding the TAA HER-2/neu. Additionally, these cells were cotransfected with IVT coding for human 4-1BBL. Transfection of DCs with 4-1BBL-IVT did not alter their typical phenotype. However, it increased the expression of the costimulatory molecules CD80 and CD40. Coadministration of HER-2/neu- and 4-1BBL-IVT resulted in an increased specific lysis of target cells by the in vitro induced CTL lines, indicating that 4-1BBL enhances their ability to elicit primary CTL responses. Interestingly, transfection of DCs with 4-1BBL-IVT did not augment their capacity to stimulate allogeneic lymphocyte responses. The here established approach of cotransfection of DCs with tumor-RNA and a second specific IVT could improve and optimize the in vitro manipulation of DCs for the induction of antigen-specific CTL responses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15877082     DOI: 10.1038/sj.cgt.7700842

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  13 in total

1.  Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients.

Authors:  Susanne M Rittig; Maik Haentschel; Katrin J Weimer; Annkristin Heine; Martin R Muller; Wolfram Brugger; Marius S Horger; Olga Maksimovic; Arnulf Stenzl; Ingmar Hoerr; Hans-Georg Rammensee; Tobias A W Holderried; Lothar Kanz; Steve Pascolo; Peter Brossart
Journal:  Mol Ther       Date:  2010-12-28       Impact factor: 11.454

Review 2.  mRNA vaccines - a new era in vaccinology.

Authors:  Norbert Pardi; Michael J Hogan; Frederick W Porter; Drew Weissman
Journal:  Nat Rev Drug Discov       Date:  2018-01-12       Impact factor: 84.694

Review 3.  Engineering dendritic cells to enhance cancer immunotherapy.

Authors:  Jeanette E Boudreau; Aude Bonehill; Kris Thielemans; Yonghong Wan
Journal:  Mol Ther       Date:  2011-04-05       Impact factor: 11.454

Review 4.  Antigen-specific vaccines for cancer treatment.

Authors:  Maria Tagliamonte; Annacarmen Petrizzo; Maria Lina Tornesello; Franco M Buonaguro; Luigi Buonaguro
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 5.  RNA vaccines in cancer treatment.

Authors:  Anita Bringmann; Stefanie Andrea Erika Held; Annkristin Heine; Peter Brossart
Journal:  J Biomed Biotechnol       Date:  2010-06-01

6.  The capacity of the TNF family members 4-1BBL, OX40L, CD70, GITRL, CD30L and LIGHT to costimulate human T cells.

Authors:  Johanna Kober; Judith Leitner; Christoph Klauser; Ramona Woitek; Otto Majdic; Johannes Stöckl; Dietmar Herndler-Brandstetter; Beatrix Grubeck-Loebenstein; Birgit M Reipert; Winfried F Pickl; Katharina Pfistershammer; Peter Steinberger
Journal:  Eur J Immunol       Date:  2008-10       Impact factor: 5.532

Review 7.  Therapeutic cancer vaccines: past, present, and future.

Authors:  Chunqing Guo; Masoud H Manjili; John R Subjeck; Devanand Sarkar; Paul B Fisher; Xiang-Yang Wang
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

Review 8.  RNA-Based Vaccines in Cancer Immunotherapy.

Authors:  Megan A McNamara; Smita K Nair; Eda K Holl
Journal:  J Immunol Res       Date:  2015-11-19       Impact factor: 4.818

Review 9.  Strategies to Genetically Modulate Dendritic Cells to Potentiate Anti-Tumor Responses in Hematologic Malignancies.

Authors:  Annelisa M Cornel; Niek P van Til; Jaap Jan Boelens; Stefan Nierkens
Journal:  Front Immunol       Date:  2018-05-18       Impact factor: 7.561

10.  Predicting combinations of immunomodulators to enhance dendritic cell-based vaccination based on a hybrid experimental and computational platform.

Authors:  Rita Ahmed; Isaac Crespo; Sandra Tuyaerts; Amel Bekkar; Michele Graciotti; Ioannis Xenarios; Lana E Kandalaft
Journal:  Comput Struct Biotechnol J       Date:  2020-08-08       Impact factor: 7.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.